Current reading list (June 2025)
We have been keeping an eye on the methods literature, and think people with an interest in the Bias Methods Group may be interested in the following articles published recently:
Akl EA, Khabsa J, Iannizzi C, et al. Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. BMJ. 2024;387:e079183.
Chan A, Boutron I, Hopewell S, Moher D, Schulz K F, Collins G S et al. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025;389:e081477.
Chan AW, Karam G, Pymento J, et al. Reporting summary results in clinical trial registries: updated guidance from WHO. Lancet Glob Health. 2025;13:e759-e68.
Cohen JF, Moher D. Generative artificial intelligence and academic writing: friend or foe? J Clin Epidemiol. 2025;179:111646.
Davidson M, Korfitsen CB, Riveros C, Chaimani A, Boutron I. Post-publication peer review and the identification of methodological and reporting issues in COVID-19 trials: a qualitative study. BMJ Evid Based Med. Published online March 3, 2025.
Duran M, Boutron I, Hopewell S, Bonnet H, Sidorkiewicz S. A cross-sectional study assessing visual abstracts of randomized trials revealed inadequate reporting and high prevalence of spin. J Clin Epidemiol. 2024;176:111544.
Graham SS, Grundy Q, Sharma N, Edward JS, Barbour JB, Rousseau JF, Majdik ZP, Bero L. Research on policy mechanisms to address funding bias and conflicts of interest in biomedical research: a scoping review. Res Integr Peer Rev. 2025;10(1):6.
Graña Possamai C, Cabanac G, Perrodeau E, Ghosn L, Ravaud P, Boutron I. Inclusion of Retracted Studies in Systematic Reviews and Meta-Analyses of Interventions: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2025;185(6):702-709.
Hopewell S, Chan A, Collins G S, Hróbjartsson A, Moher D, Schulz K F et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123.
Lunny C, Higgins JPT, White IR, et al. Risk of Bias in Network Meta-Analysis (RoB NMA) tool. BMJ. 2025;388:e079839.
Qureshi R, Naaman K, Quan NG, et al. Development and Evaluation of a Framework for Identifying and Addressing Spin for Harms in Systematic Reviews of Interventions. Ann Intern Med. 2024;177:1089-1098.
Ramirez HW, Chiaborelli M, Schönenberger CM, et al. Do peer reviewers comment on reporting items as instructed by the journal? A secondary analysis of two randomized trials. J Clin Epidemiol. 2025;183:111818.
Rolland P, Jutel A, Douget L, Naudet F, Roy JC. Incomplete reporting of adverse events in duloxetine trials: a meta-research survey of randomized controlled trials vs placebo. J Clin Epidemiol. 2025;180:111677.
Salazar J, Moustgaard H, Bracchiglione J, Hróbjartsson A. Empirical evidence of observer bias in randomised clinical trials: updated and expanded analysis of trials with both blinded and non-blinded outcome assessors. J Clin Epidemiol. 2025:111787.
Siedler MR, Tangri N, AlShenaiber L, et al. Certainty of evidence assessment in high-impact medical journals: a meta-epidemiological survey. Cochrane Ev Synth. 2025;3:e70014.
Showell MG, Cole S, Clarke MJ, DeVito NJ, Farquhar C, Jordan V. Time to publication for results of clinical trials. Cochrane Database Syst Rev. 2024;11:MR000011.
Silva S, Singh S, Kashif S, Ogilvie R, Pinto RZ, Hayden JA. Many randomized trials in a large systematic review were not registered and had evidence of selective outcome reporting: a metaepidemiological study. J Clin Epidemiol. 2024;176:111568.
Tian Y, Lu H, Zhou W, Suhail AD, Furuya-Kanamori L, Lin L, Loke Y, Vohra S, Xu C, Xu Z. Prospective registration was associated with a reduced risk of bias for randomized controlled trials: a meta-research study. J Clin Epidemiol. 2025;183:111819.
Vijfschagt ND, Burger H, Berger MY, Fanshawe TR, van den Bruel A, Leeflang MMG, de Boer MR, Holtman GA. Variation in sensitivity and specificity of diverse diagnostic tests across health-care settings: a meta-epidemiological study. J Clin Epidemiol. 2025;183:111816.
Wang Y, Keitz S, Briel M, et al. Development of ROBUST-RCT: Risk Of Bias instrument for Use in SysTematic reviews-for Randomised Controlled Trials. BMJ. 2025;388:e081199.
Wrightson JG, Blazey P, Moher D, Khan KM, Ardern CL. GPT for RCTs? Using AI to determine adherence to clinical trial reporting guidelines. BMJ Open. 2025;15:e088735.
Former reading lists
The November 2024 reading list can be found here.
The December 2023 reading list can be found here.
The January 2023 reading list can be found here.
The November 2022 reading list can be found here.
The December 2021 reading list can be found here.
The March 2021 reading list can be found here.
The July 2020 reading list can be found here.
The December 2019 reading list can be found here.
The March 2019 reading list can be found here.
The August 2018 reading list can be found here.
The February 2018 reading list can be found here.
